Skip to content
Hengrui Pharma
-
Bristol Myers Squibb bets US$15.2B on Hengrui partnership to accelerate global drug pipeline
Hengrui will oversee the initial human clinical studies for the immunology assets licensed from BMS, a move intended to speed up proof-of-concept data generation.